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Abstract
Background Treatment with apremilast has recently demonstrated clinically meaningful improvement in moderate
hidradenitis suppurativa (HS).
Objective To evaluate the change in expression of inﬂammatory markers in lesional skin of HS patients receiving
apremilast 30 mg twice daily (n = 15) for 16 weeks compared with placebo (n = 5).
Methods At baseline, 5-mm punch biopsies were obtained from an index lesion (HSL) and non-lesional (HSN) skin in
the same anatomical area. Subsequent HSL samples were taken as close as possible to the previously biopsied site at
week 4 and week 16. After sampling, biopsies were split; one half was processed for in vivo mRNA analysis using real-
time quantitative PCR; the other half was cultured for ex vivo protein analysis using a proximity extension assay (Olink).
Linear mixed effects models were calculated to compare the levels of inﬂammatory markers in HSL skin between apremi-
last and placebo over time.
Results At baseline, 17 proteins with a fold change >2 in HSL vs. HSN skin were identiﬁed in 20 patients. The top ﬁve
were IL-17A (5), S100A12, CST5, IL-12/23p40, CD6 (1) with fold changes ranging from 6.6 to 1638, respectively (FDR
<0.044). Linear mixed effects models for 75 assays were calculated. Protein levels of S100A12 decreased during treat-
ment in the apremilast group compared with the placebo group (p = 0.014, FDR = 0.186). None of the 14 genes exhib-
ited signiﬁcant changes in expression over time. However, an evident downward trend in relative mRNA expression of
IL-17A and IL-17F was demonstrated in patients receiving apremilast.
Conclusion We did not detect statistically signiﬁcant changes in inﬂammatory markers in HSL skin of HS patients
receiving apremilast compared with placebo, despite clinical improvement in the apremilast group. Nonetheless,
S100A12 and IL-17A were signiﬁcantly elevated in HSL skin and showed a decrease in response to apremilast. The
translational model in clinical trials involving HS clearly needs further improvement.
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Introduction
Hidradenitis suppurativa (HS) is a chronic, recurrent, auto-
inflammatory skin disorder with limited effective treatment
options.1 Recently, treatment with apremilast for 16 weeks has
demonstrated clinically meaningful improvement in moderate
HS.2 In this study (NCT03238469; EudraCT 2016-000859-27),
twenty patients with moderate HS (HS-PGA score of 3) were
randomized in a 3 : 1 ratio to receive blinded treatment of
apremilast 30 mg twice daily or placebo, respectively. Demo-
graphic and disease characteristics were similar between
Ethical review board approval: IRB of the Erasmus University Medical Center
(NL.57003.078.16, MEC-2016-377)
Trial registration number: NCT03049267 on ClinicalTrials.gov, registered 25
October 2016.
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treatment arms. The mean age of the study population was
35 years (range: 21–64), most patients were female (17/20) and
current smoker (16/20), the mean BMI was 32.7  standard
deviation (SD) 6.2, and the mean abscess and inflammatory
nodule (AN) count was 6.0  1.8. The objective of this transla-
tional study was to evaluate the change in expression of inflam-
matory markers in lesional skin of HS patients receiving
apremilast 30 mg twice daily for 16 weeks compared with
placebo.
Material and methods
Ethical statement
This investigator-initiated trial was approved by the medical
ethics committee of the Erasmus University Medical Center Rot-
terdam, The Netherlands (NL.57003.078.16), and conducted
according to the Declaration of Helsinki principles. All patients
provided written informed consent for study participation and
use of their skin biopsies.
Biopsy procedures and sample processing
At baseline, two 5-mm punch biopsies were taken: one was
obtained from an erythematous, indurated, inflamed lesion, i.e.
the index lesion (HSL), and one from the normal-appearing
unaffected non-lesional (HSN) skin in the same anatomical area
(Fig. 1). Subsequent HSL skin samples were taken as close as
possible to the previously biopsied index site at week 4 (early
response) and week 16 (end of study). After sampling, biopsies
were split whereby one half was processed for mRNA analysis of
the biopsy, representing the in vivo gene expression, and the
other half was cultured for ex vivo protein analysis. The super-
natants and the biopsies in 250 lL lysis buffer containing 1% ß-
mercaptoethanol were transferred to a polypropylene tube and
stored at 20°C until further analysis.
Ex vivo skin culture and protein quantiﬁcation
After sampling, half of the 5-mm biopsy was cultured for 24 h at
37°C in an atmosphere of 5% CO2 and 98% humidity in a tran-
swell system (Netwell; Costar, Cambridge, MA, USA) as previ-
ously described.3,4 In short, samples were placed in a 12-well
plate with the epidermis exposed to the air and the dermis
immersed in 1 mL Iscove’s modified Dulbecco’s medium
(Gibco, Paisley, UK) containing 0.5% human AB serum, peni-
cillin (100 U/mL) and streptomycin (100 U/mL). A broad spec-
trum of 92 inflammatory markers was measured in the
supernatant using the Olink Proseek Multiplex Inflammation
panel (Olink Proteomics, Uppsala, Sweden).
In vivo gene expression
Total RNA was isolated using the GenElute Mammalian Total
RNA Miniprep Kit (Sigma-Aldrich, St. Louis, MA, USA), treated
with 0.1 U/lL DNAse (Invitrogen, Carlsbad, CA, USA) and
cDNA was synthesized with SuperScript II reverse transcriptase,
random hexamer primers (Invitrogen) and oligo(dT)15
(Promega, Madison, WI, USA). Primers and probes were
designed and chosen using ProbeFinder Software and the
Universal Probe Library (Roche Applied Science, Indianapolis,
IN, USA). ABL1 was used as housekeeping gene. Real-time
quantitative PCR for 14 genes (IFN-ɣ, TNF-a, IL-1ß, IL-6, IL-8,
IL-10, IL-23p19, IL-12/23p40, IL-17A, IL-17F, IL-31, CXCL-10,
CCL-5 and MPO) was performed with the ViiA7 System and
using the QuantStudio Real-Time PCR Software version 1.3
(Applied Biosystems, Waltham, MA, USA).
Statistical analysis
Protein data are presented as normalized protein expression
(NPX), which are log2-transformed arbitrary units. Relative
mRNA expression levels for week 4 and week 16 were calculated
(a) (b) (c)
Figure 1 Biopsy procedure in a patient with a good clinical response to apremilast. Note that all deep-seated lesions have resolved. Ery-
thematous lesions seen at week 16 are scars and superﬁcial folliculitis. Panel (a; left) Baseline. A 5-mm punch biopsy was obtained from
an erythematous, indurated, inﬂamed lesion (arrow pointing to index lesion). An additional 5-mm punch biopsy of the non-lesional skin
was taken from the same anatomical area to serve as control (circle within the square). Panel (b; middle) Week 4 and Panel (c; right) Week
16. Subsequent skin samples were taken as close as possible to the previously biopsied index site (small circles within dashed line).
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using the 2DDCT method using a baseline value of 1 for each
individual sample.5
First, differentially expressed proteins at baseline were
explored by calculating a fold change with the median NPX of
HSL skin divided by the median NPX of HSN skin. If the fold
change was more than 2, a Wilcoxon signed rank test was subse-
quently used to pairwise compare protein levels between HSL
and HSN skin. Second, linear mixed effects models and associ-
ated ANOVA for repeated measures were calculated to compare
inflammatory protein and mRNA expression levels between
apremilast and placebo over time. Fixed effects were treatment,
time and treatment 9 time. Third, the Spearman’s rho was used
to assess translational linkage, i.e. correlation between the levels
of inflammation and the AN count.
A two-sided P-value below 0.05 was considered significant.
P-values were adjusted for multiple testing within each test
using the Benjamini-Hochberg approach. Statistical analyses
were conducted in R Statistical Software version 3.5 (R Foun-
dation for Statistical Computing, Vienna, Austria) using the
lmerTest package.
Results
At baseline, 17 proteins with a fold change >2 were identified
(Table 1). The top-five were IL-17A (5), S100A12, CST5, IL-
12p40, CD6 (1) with fold changes ranging from 6.6 to 1638,
respectively (FDR ≤0.044). Out of 92 Olink assays, 75 were
included in the linear mixed effects models. The assays
removed had less than 25% detectability including TNF-a
and IFN-c. Only the protein levels of S100A12 decreased over
time in the apremilast vs. placebo group, statistically non-
Table 1 Proteins with a fold change >2 in HSL vs. HSN skin at baseline
# Protein Fold change
HSL/HSN
NPX HSL
n = 20
NPX HSN
n = 20
Unadj. P-value Adj. P-value Missing data
Median IQR Median IQR FDR %
1 CD6 1638 3.5 2.0–4.1 0.002 0.0–0.2 3.4 e-07 0.018 None
2 IL-12p40 38 0.9 0.5–1.8 0.024 0.0–0.1 7.2 e-06 0.038 7.5
3 CST5 23 0.9 0.6–1.1 0.041 0.0–0.1 6.1 e-07 0.024 1.1
4 S100A12 11 4.5 3.1–6.3 0.4 0.4–0.8 2.7 e-05 0.041 20.0
5 IL-17A 6.6 3.1 1.8–3.8 0.5 0.5–0.6 2.9 e-05 0.044 26.3
6 TNFSF14 4.5 3.4 2.5–4.1 0.8 0.4–1.0 1.0 e-06 0.029 6.3
7 AXIN1 4.4 1.9 1.7–2.1 0.4 0.4–0.5 8.8 e-07 0.026 8.8
8 b-NGF 3.2 1.1 0.6–1.4 0.3 0.3–0.6 5.8 e-04 0.047 15.0
9 TNFSF11 3.1 2.2 1.2–3.3 0.7 0.7–0.7 4.6 e-07 0.021 28.8
10 CD244 3.0 2.7 2.3–3.1 0.9 0.9–0.9 1.1 e-07 0.012 23.8
11 CD5 3.0 7.3 5.9–7.6 2.5 2.2–2.6 1.3 e-08 0.003 None
12 TNFRSF9 2.9 6.4 5.2–7.6 2.2 1.8–2.7 1.3 e-08 0.006 1.3
13 OSM 2.9 6.4 6.0–7.8 2.2 1.3–3.4 4.0 e-06 0.035 3.8
14 SIRT2 2.8 5.0 4.5–5.4 1.8 1.5–1.9 1.9 e-07 0.015 5.0
15 GDNF 2.7 2.9 2.0–3.8 1.1 0.8–1.2 1.6 e-06 0.032 5.0
16 IL-18R1 2.3 4.2 3.6–5.2 1.8 1.7–2.0 1.3 e-08 0.009 None
17 ST1A1 2.1 1.5 0.8–1.8 0.7 0.5–1.2 1.3 e-02 0.050 10.0
Missing data: samples with NPX-values below background level throughout all samples, i.e. HSN and HSL baseline, HSL week 4 and HSL week 16. NPX: a
high NPX value corresponds with a high protein concentration. Unadj. P-value: unadjusted P-value by Wilcoxon signed rank, NPX HSL vs. NPX HSN. Adj.
P-value (FDR): adjusted P-value Benjamini Hochberg test, NPX HSL vs. NPX HSN.
FDR: false discovery rate; HS: hidradenitis suppurativa; HSL: HS lesional; HSN: HS non-lesional; IQR: interquartile range; NPX: normalized protein
expression.
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Figure 2 Protein levels of S100A12 in patients receiving apremi-
last (n = 15) and placebo (n = 5), linear mixed effect model:
P = 0.014, FDR = 0.186. t: week. Data at week 16 for two patients
receiving apremilast are missing as these two patients discontin-
ued after respectively week 4 and week 8.
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significant after correction for multiple testing (P = 0.014,
FDR = 0.186; Fig. 2).
None of the 14 genes analysed by linear mixed effects models
yielded significant differences. Only the relative mRNA expres-
sion of IL-17A and IL-17F demonstrated an evident but non-sig-
nificant downward trend in patients receiving apremilast vs.
placebo (P > 0.05; Fig. 3). In addition, there was no correlation
between S100A12 protein levels or IL-17A/F mRNA expression
and the favourable clinical response in the apremilast group as
measured by the AN count (data not shown).
Discussion
This translational study aimed to identify inflammatory skin
markers in response to apremilast 30 mg twice daily for
16 weeks in patients with moderate HS, which showed positive
clinical results and have been published previously.2 However,
S100A12 protein levels and IL-17A and IL-17F mRNA expres-
sion showed a clear but non-significant decrease in patients
receiving apremilast compared with placebo.
S100A12 (calgranulin C, EN-RAGE) is a pro-inflammatory,
calcium-binding antimicrobial protein that interacts with the
receptor for advanced glycation end products (RAGE) and is
overexpressed in various inflammatory skin diseases, e.g. pso-
riasis.6,7 Previously, S100A8 and S100A9 (calprotectin or cal-
granulin A/B) have been demonstrated to be elevated in the
serum and lesional skin of HS patients.8,9 It is known that
IL-17 is a potent inducer of S100A8 and S100A9 in ker-
atinocytes.10,11 The other way around, S100A12 stimulates T
cells to produce IL-17A.12 Thus, elevated levels of IL-17A and
S100A12 in HSL skin at baseline and the responsiveness of
these inflammatory markers to apremilast treatment is not
surprising. Moreover, apremilast’s impact on the Th17 path-
way was recently demonstrated by the significant reduction of
IL-17A and IL-17F protein levels in the plasma of psoriasis
patients.13
The non-significant findings using a broad panel of
inflammatory markers may be explained by the regression to
the mean phenomenon, particularly at the individual level.13
The highly inflammatory index lesions could have sponta-
neously improved over time in the context of the fluctuating
nature of the disease, especially in the placebo group. The
effect of regression to the mean increases with larger mea-
surement variability.14 Expanding the number of biopsies
from index lesions, representing several degrees of
inflammation, would theoretically be a solution. However,
taking more biopsies would not be feasible for ethical
reasons.
Another explanation for the decreased levels of inflammation
over time in both groups could be that the inflammatory infil-
trate of the index lesion was gradually reduced by successively
taking biopsies from the same nodule. Moreover, the substrate
for the foreign body inflammation such as hair fragments and
keratin fibres, may have also been (partially) removed by the
biopsy procedure.15 In addition, this exploratory study might be
underpowered which may also have resulted in non-significant
results.
Previously, two prospective uncontrolled studies investigating
infliximab and ustekinumab in HS were also unable to link
translational data to the clinical response.16,17 However, in these
studies, only inflammatory markers in serum were investigated.
Strengths of our study include the placebo-controlled trial
design, the use of skin (target organ) instead of serum or plasma,
and the standardized biopsy procedure of an index lesion. A
limitation is the small study population.
In conclusion, this translational study investigating apremi-
last in moderate HS did not detect statistically significant
changes in important inflammatory markers in lesional skin
compared with placebo over 16 weeks of treatment, despite
positive clinical findings. Nonetheless, related S100A12 and
IL-17A were significantly elevated in HSL skin and showed a
decline only in the apremilast group. In addition, our
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Figure 3 Relative mRNA expression levels of IL-17A and
IL-17F in patients receiving apremilast (n = 15) and placebo
(n = 5). IL: interleukin; t: week. Panel (a; above) IL-17A. At
t = 16 in the apremilast group: one data point is out of the
y-axis range. Linear mixed effect model: P > 0.05. Panel
(b; below). IL-17F. At both t = 4 and t = 16 in the apremilast
group, one data point is out of the y-axis range. Linear mixed
effect model: P > 0.05. Data at week 16 for two patients
receiving apremilast are missing as these two patients
discontinued after respectively week 4 and week 8.
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findings highlight the challenge of assessing pharmacodynam-
ics in the skin in a highly fluctuating inflammatory disease.
A better translational model in clinical trials involving HS
has yet to be developed.
Acknowledgements
We thank Eddy Florencia and Patrick Asmawidjaja for providing
technical assistance in processing the skin samples.
References
1 Zouboulis CC, Bechara FG, Dickinson-Blok JL et al. Hidradenitis sup-
purativa/acne inversa: a practical framework for treatment optimization -
systematic review and recommendations from the HS ALLIANCE work-
ing group. J Eur Acad Dermatol Venereol 2018. https://doi.org/10.1111/
jdv.15233
2 Vossen ARJV, van Doorn MBA, van der Zee HH, Prens EP. Apremilast for
moderate hidradenitis suppurativa: results of a randomized controlled trial.
J Am Acad Dermatol 2018. pii: S0190-9622(18)32202–3.
3 Wei L, Debets R, Hegmans JJ et al. IL-1 beta and IFN-gamma induce the
regenerative epidermal phenotype of psoriasis in the transwell skin organ
culture system. IFN-gamma up-regulates the expression of keratin 17 and
keratinocyte transglutaminase via endogenous IL-1 production. J Pathol
1999; 187: 358–364.
4 Companjen AR, van der Wel LI, Wei L et al. A modified ex vivo skin
organ culture system for functional studies. Arch Dermatol Res 2001; 293:
184–190.
5 Rao X, Huang X, Zhou Z et al. An improvement of the 2^(-delta delta
CT) method for quantitative real-time polymerase chain reaction data
analysis. Biostat Bioinforma Biomath 2013; 3: 71–85.
6 Eckert RL, Broome AM, Ruse M et al. S100 proteins in the epidermis. J
Invest Dermatol 2004; 123: 23–33.
7 Wilsmann-Theis D, Wagenpfeil J, Holzinger D et al. Among the
S100 proteins, S100A12 is the most significant marker for
psoriasis disease activity. J Eur Acad Dermatol Venereol 2016; 30:
1165–1170.
8 Lima AL, Karl I, Giner T et al. Keratinocytes and neutrophils are impor-
tant sources of proinflammatory molecules in hidradenitis suppurativa.
Br J Dermatol 2016; 174: 514–521.
9 Wieland CW, Vogl T, Ordelman A et al. Myeloid marker S100A8/A9 and
lymphocyte marker, soluble interleukin 2 receptor: biomarkers of
hidradenitis suppurativa disease activity? Br J Dermatol 2013; 168: 1252–
1258.
10 Cho KA, Suh JW, Lee KH et al. IL-17 and IL-22 enhance skin inflam-
mation by stimulating the secretion of IL-1beta by keratinocytes via
the ROS-NLRP3-caspase-1 pathway. Int Immunol 2012; 24: 147–158.
11 Bai B, Yamamoto K, Sato H et al. Complex regulation of S100A8 by IL-
17, dexamethasone, IL-4 and IL-13 in HaCat cells (human keratinocyte
cell line). J Dermatol Sci 2007; 47: 259–262.
12 Kessel C, Lippitz K, Weinhage T et al. Proinflammatory cytokine envi-
ronments can drive interleukin-17 overexpression by gamma/delta T cells
in systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2017; 69:
1480–1494.
13 Garcet S, Nograles K, Correa da Rosa J et al. Synergistic cytokine effects
as apremilast response predictors in patients with psoriasis. J Allergy Clin
Immunol 2018; 142: 1010–1013.e6.
14 Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it
is and how to deal with it. Int J Epidemiol 2005; 34: 215–220.
15 van der Zee HH, de Ruiter L, Boer J et al. Alterations in leucocyte subsets
and histomorphology in normal-appearing perilesional skin and early
and chronic hidradenitis suppurativa lesions. Br J Dermatol 2012; 166:
98–106.
16 Blok JL, Li K, Brodmerkel C et al. Ustekinumab in hidradenitis suppura-
tiva: clinical results and a search for potential biomarkers in serum. Br J
Dermatol 2016; 174: 839–846.
17 Montaudie H, Seitz-Polski B, Cornille A et al. Interleukin 6 and high-sen-
sitivity C-reactive protein are potential predictive markers of response to
infliximab in hidradenitis suppurativa. J Am Acad Dermatol 2017; 76:
156–158.
© 2018 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology.
JEADV 2018
Apremilast in hidradenitis suppurativa 5
